Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer.

ABSTRACT:

Background

Intra-tumour genetic heterogeneity has been reported in both leukaemias and solid tumours and is implicated in the development of drug resistance in CML and AML. The role of genetic heterogeneity in drug response in solid tumours is unknown.

Methods

To investigate intra-tumour genetic heterogeneity and chemoradiation response in advanced cervical cancer, we analysed 10 cases treated on the CTCR-CE01 clinical study. Core biopsies for molecular profiling were taken from four quadrants of the cervix pre-treatment, and weeks 2 and 5 of treatment. Biopsies were scored for cellularity and profiled using Agilent 180k human whole genome CGH arrays. We compared genomic profiles from 69 cores from 10 patients to test for genetic heterogeneity and treatment effects at weeks

SUBMITTER: Cooke SL 

PROVIDER: S-EPMC3031882 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature